VNDA May 2024 6.000 call
| Previous Close | 0.2500 |
| Open | 0.3500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 6.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.1500 - 0.3500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
PR NewswireVanda Pharmaceuticals Reports First Quarter 2024 Financial Results
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2024.
- PR Newswire
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC ("Future Pak") to acquire the Company. The revised proposal consists of a $7.25 to $7.75 per share in cash plus certain Contingent Value Rights ("CVRs"). The amended proposal follows Vanda's review and rejection of a prior unsolicited proposal from Future Pak to acquire the Company for $7.25-$7.75 per share.
- Reuters
UPDATE 3-Future Pak sweetens take-private offer for Vanda Pharmaceuticals
Privately held contract manufacturer Future Pak said on Tuesday it will sweeten its buyout offer for Vanda Pharmaceuticals to include contingent value rights, in addition to the proposed offer price of $7.25 to $7.75 per share in cash. The rights would provide additional benefits to Vanda shareholders if certain performance targets are met. Future Pak said the revised offer includes up to $260 million of potential contingent value rights, or CVR payments, and represents up to $4.37 per share in additional value for Vanda.
